Orphan drugs to be wholly reviewed.

The KFDA is going to reshuffle the orphan drug administrative regulation for the purpose of adjusting it more reasonable and eliminating any possible short-cut applications to its nomination.

At present the KFDA is considering to exclude some items out of the total 85 orphan drugs when the drug was already available locally as other substituted drugs and had a market volume of over U$500,000...